Kadmon Holdings, which is developing kinase inhibitors for autoimmune disease, fibrosis and solid tumors, raised $75 million by offering 6.3 million shares at $12. Kadmon Holdings plans to list on the NYSE under the symbol KDMN. Citi and Jefferies acted as lead managers on the deal.
